HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
Phase II Study: To evaluate the safety and preliminary efficacy of HMPL-523 in adult patients
with wAIHA
Phase III Studies: Confirmation of Efficacy safety and of HMPL-523 in Adult Patients With
wAIHA